CONCERTA XL 18 mg prolonged-release tablets

*
Pharmacy Only: Prescription
  • Company:

    Janssen Sciences Ireland
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

Updated on 09 November 2022

File name

PI-Concerta XL-18mg-Ireland-English-IAIN_111.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

DE/H/6007/001-004/IA/111 - Update EUPI following PRAC recommendation - EoP 2-November-2022

Updated on 09 November 2022

File name

PIL-Concerta XL-18-36 mg-Ireland-English-IAIN_111.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

DE/H/6007/001-004/IA/111 - Update EUPI following PRAC recommendation - EoP 2-Nov-22

Updated on 05 August 2022

File name

PI-Concerta XL-18mg-Ireland-English-II_107.pdf

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

DE_H_6007_001-004_II_107_ Adult de novo Indication

Updated on 05 August 2022

File name

PIL-Concerta XL-18-36 mg-Ireland-English-II_107.pdf

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Changes to therapeutic indications

Free text change information supplied by the pharmaceutical company

DE_H_6007_001-004_II_107_ Adult de novo Indication

Updated on 16 May 2022

File name

PI-Concerta-18mg-Ireland-English-DE_H_6007_001-004_IA_104_consolidated_II_92.pdf

Reasons for updating

  • Other

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Correction to add back 2 missing paragraphs which already had been approved.

Section 4.4:

Use with serotonergic medicinal products

Serotonin syndrome has been reported following coadministration of methylphenidate with serotonergic medicinal products. If concomitant use of methylphenidate with a serotonergic medicinal product is warranted, prompt recognition of the symptoms of serotonin syndrome is important. These symptoms may include mental‑status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea). Methylphenidate must be discontinued as soon as possible if serotonin syndrome is suspected.

Section 4.5:

Use with serotonergic medicinal products

There have been reports of serotonin syndrome following coadministration of methylphenidate with serotonergic medicinal products. If concomitant use of methylphenidate with a serotonergic medicinal product is warranted, prompt recognition of the symptoms of serotonin syndrome is important (see section 4.4). Methylphenidate must be discontinued as soon as possible if serotonin syndrome is suspected. 

Updated on 12 October 2020

File name

SPC-Concerta-18mg-Ireland-English-DE_H_6007_001-004_IA_104_EDMS-ERI-138444855_11.0-C25-7Oct2020-cl.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 12 October 2020

File name

PIL-Concerta-18-36 mg-Ireland-English-DE_H_6007_001-004_IA_104_EDMS-ERI-183377703_8.0-7Oct2020-cl.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 09 September 2020

File name

IE-Concerta-PIL 18_36mg.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Concerta XL contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium‑free’.

 

 

 

 

Updated on 05 August 2020

File name

CONCERTA 18 XL_Tablet, Film Coated, Extended Release clean.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

update in line with excipient guideline

Updated on 12 April 2019

File name

IE-Concerta-PIL-18-36mg-Brexit-clean.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 12 April 2019

File name

IE-Concerta-SmPC-18mg-C22-29mar19-Brexit-clean.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 06 March 2019

File name

UK-IE-Concerta-PIL-18-36-54mg-II092-clean.pdf

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 06 March 2019

File name

IE-Concerta XL-SmPC-18mg-C21-II092-Clean.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

CCDS Dec 2016 (092) safety change

Updated on 17 July 2018

File name

PIL-Concerta XL-18-36-54mg-C20-11jul18-clean.pdf

Reasons for updating

  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision

Updated on 17 July 2018

File name

Concerta XL-IE-SmPC-18mg-C20-11jul18-clean.pdf

Reasons for updating

  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

6.1     List of excipients

 

Butylhydroxytoluene (E321)

Cellulose acetate

Hypromellose (E464)

Phosphoric acid concentrated

Poloxamer 188

Polyethylene oxides 200K and 7000K

Povidone K29-32

Sodium chloride

Stearic acid

Succinic acid

Iron oxide black (E172)

Iron oxide yellow (E172)

 

Film Coat

 

Iron oxide yellow (E172)

Hypromellose (E464)

Lactose monohydrate

Stearic acid

Titanium dioxide (E171)

Triacetin

 

Clear Coat

 

Carnauba wax

Hypromellose (E464)

Macrogol 400

 

Printing Ink

 

Iron oxide black (E172)

Hypromellose (E464)

Isopropyl alcohol

Propylene glycol

Purified water

Updated on 19 February 2018

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 19 February 2018

File name

PIL_9209_403.pdf

Reasons for updating

  • New PIL for new product

Updated on 19 February 2018

File name

PIL_9209_403.pdf

Reasons for updating

  • New PIL for new product

Updated on 19 February 2018

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4       Special warnings and precautions for use

Aggressive or hostile behaviour

The emergence or worsening of aggression or hostility can be caused by treatment with stimulants. Aggression has been reported in patients treated with methylphenidate (see section 4.8). Patients treated with methylphenidate should be closely monitored for the emergence or worsening of aggressive behaviour or hostility at treatment initiation, at every dose adjustment and then at least every 6 months and every visit. Physicians should evaluate the need for adjustment of the treatment regimen in patients experiencing behaviour changes bearing in mind that upwards or downwards titration may be appropriate. Treatment interruption can be considered.

Anxiety, agitation or tension

Anxiety, agitation and tension have been reported in patients treated with methylphenidate (see section 4.8). Methylphenidate is also associated with the worsening of pre-existing anxiety, agitation or tension, and anxiety led to discontinuation of methylphenidate in some patients. Clinical evaluation for anxiety, agitation or tension should precede use of methylphenidate and patients should be regularly monitored for the emergence or worsening of these symptoms during treatment, at every adjustment of dose and then at least every 6 months or every visit.

4.6     Fertility, pregnancy and lactation

Methylphenidate has been found in the breast-milk of a woman treated with methylphenidate. Methylphenidate is excreted in human milk. Based on reports of breast milk sampling from five mothers, methylphenidate concentrations in human milk resulted in infant doses of 0.16% to 0.7% of the maternal weight‑adjusted dosage, and a milk to maternal plasma ratio ranging between 1.1 and 2.7.

5.2     Pharmacokinetic properties

Replacement of (0-inf) with inf throughout

Updated on 19 February 2018

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision
  • Correction of spelling/typing errors

Updated on 19 April 2017

Reasons for updating

  • Correction of spelling/typing errors

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Adminatrative changes - No change to SPC content.

Updated on 20 March 2017

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Inclusion of the following wording on Priapism in Section 4.4:

Priapism

Prolonged and painful erections have been reported in association with methylphenidate products, mainly in association with a change in the methylphenidate treatment regimen. Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.

Addition of Priapism, Erection increased and Prolonged erection as adverse reaction with 'not known' frequency in Section 4.8.

Updated on 17 March 2017

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 18 May 2016

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8

Addition of

 

Hepatobiliary disorders –very rare- acute hepatic failure

 

Other ADR changes =changed system organ class


System Organ Class

Adverse Drug Reaction

Frequency

Very common

Common

Uncommon

Rare

Very rare

Not known

 

Psychiatric disorders*

Insomnia, Nervousness

Anorexia, Affect lability, Aggression*, Agitation*, Anxiety*, Depression*#, Irritability, Abnormal behaviour, Mood swings, Tics*, Initial insomnia#, Depressed mood#, Depression#, Libido decreased#, Tension#, Bruxism#, Panic attack#

Psychotic disorders*,  Auditory, visual and tactile hallucination*, Anger, Suicidal ideation*, Mood altered, Restlessness, Tearfulness, Worsening of pre-existing tics of Tourette’s syndrome*, Logorrhoea, Hypervigilance, Sleep disorder

Mania*, Disorientation, Libido disorder, Confusional state

Suicidal attempt (including completed suicide)*, Transient depressed mood*, Abnormal thinking, Apathy, Repetitive behaviours, Over-focussing

Delusions*, Thought disturbances*, dependence. Cases of abuse and dependence have been described, more often with immediate release formulations

 

Hepatobiliary disorders

 

Alanine aminotransferase increased#

Hepatic enzyme elevations increased

 

Abnormal liver function, including acute hepatic failure and hepatic coma, Blood alkaline phosphatase increased, Blood bilirubin increased

 

 

Investigations

 

Changes in blood pressure and heart rate (usually an increase)*, Weight decreased*, Alanine aminotransferase increased#

Cardiac murmur*, Hepatic enzyme increased

 

Blood alkaline phosphatase increased, Blood bilirubin increased, Platelet count decreased, White blood cell count abnormal

 

 

*      See section 4.4

#    Frequency derived from adult clinical trials and not on data from trials in children and adolescents; may also be relevant for children and adolescents.

    Frequency derived from clinical trials in children and adolescent and reported at a higher frequency in clinical trials in adult patients.

 

Updated on 17 May 2016

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 20 July 2015

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 4.1, 4.2, 4.3 (admin)

Update to section 4.8 _ ADR reporting statement

Update to section 4.9 (overdose)

Treatment

 

There is no specific antidote to methylphenidate overdosage.

 

Treatment consists of appropriate supportive measures.

 

The patient must be protected against self-injury and against external stimuli that would aggravate overstimulation already present. . If the signs and symptoms are not too severe and the patient is conscious, gastric contents may be evacuated by induction of vomiting or gastric lavage. Before performing gastric lavage, control agitation and seizures if present and protect the airway. Other measures to detoxify the gut include administration of activated charcoal and a cathartic. In the presence of severe intoxication, a carefully titrated dose of a benzodiazepine be given before performing gastric lavage The efficacy of activated charcoal has not been established.

 

 

Updated on 17 July 2015

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 04 September 2014

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.7:

When early discharge is envisaged, patients should be advised not to drive or operate machinery for the 24 hours following administration.

This medicine can impair cognitive function and can affect a patient’s ability to drive safely. When prescribing this medicine, patients should be told:

•              The medicine is likely to affect your ability to drive

•              Do not drive until you know how the medicine affects you

•              It may be an offence to drive while under the influence of this medicine

 

Updated on 02 September 2014

Reasons for updating

  • Change to information about driving or using machinery
  • Change to date of revision

Updated on 04 March 2013

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.5 Interaction:

 

Use with centrally acting alpha‑2 agonists (e.g. clonidine)

 

Serious adverse events, including sudden death, have been reported in concomitant use with clonidine.

The  long-term safety of using methylphenidate in combination with clonidine or other centrally acting alpha‑2 agonists has not been systematically evaluated.

Updated on 28 November 2012

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 27 November 2012

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8

Addition of  “ logorrhoea” under Psychiatric Disorders~ uncommon and “pollakiura” under renal and urinary disorders ~uncommon

Updated on 14 September 2011

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4 Special warnings and precautions

Aggressive or hostile behaviour

The emergence or worsening of aggression or hostility can be caused by treatment with stimulants. Patients treated with methylphenidate should be closely monitored for the emergence or worsening of aggressive behaviour or hostility at treatment initiation, at every dose adjustment and then at least every 6 months and every visit. Physicians should evaluate the need for adjustment of the treatment regimen in patients experiencing behaviour changes bearing in mind that upwards or downwards titration may be appropriate. Treatment interruption can be considered.

Section 4.9 Overdose

When treating patients with overdose, allowances must be made for the delayed release of methylphenidate from this formulations with extended durations of action

Updated on 16 August 2011

Reasons for updating

  • Correction of spelling/typing errors

Updated on 27 June 2011

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2 Posology and method of administration.
under 'Adults' change to advice to allow continuation into adulthood.

Now states; 'In adolescents whose symptoms persist into adulthood and who have shown clear benefit from treatment, it may be appropriate to continue treatment into adulthood. However, start of treatment with CONCERTA XL in adults is not appropriate (see sections 4.4 and 5.1).'

Section 4.4 Special warnings and precautions:

Use in adults . text update to :'  Safety and efficacy have not been established for the initiation of treatment in adults or the routine continuation of treatment beyond 18 years of age. If treatment withdrawal has not been successful when an adolescent has reached 18 years of age continued treatment into adulthood may be necessary. The need for further treatment of these adults should be reviewed regularly and undertaken annually.
Cardiovascular status:  'The possibility of clinical complications cannot be excluded as a result of the effects observed in the clinical trial data especially when treatment during childhood/adolescence is continued into adulthood.
Section 4.8 Undesirable effects
 Addition of adverse events seen in adult clinical trials.

Section 5.1   Pharmacodynamics:
addition of adult clinical trial efficacy data (18 to 65 years)

Updated on 24 June 2011

Reasons for updating

  • Change to, or new use for medicine
  • Change to side-effects
  • Change to date of revision

Updated on 10 November 2010

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 section 4.2 addition of 'hydrochloride' after methylphenidate

Section 4.8 _ no addtional adverse effects chnage in frequency of several ADRS

Updated on 01 November 2010

Reasons for updating

  • Change to side-effects

Updated on 11 March 2010

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.1

Therapeutic Indications

Treatment must be under the supervision of a specialist in childhood behavioural disorder, and emphasis on the need for  remedial measures before introducing pharmacotherapy.

4.2

Posology and method of administration

Addition of Phaecochromocytoma

4.3

Contraindications

Addition of Phaecochromocytoma

4.4

Special Warnings and Precautions for Use

More detailed information on long term effects, ongoing monitoring requirements, and withdrawing medication for trial period

4.5

Interaction with other medicinal products and other forms of interaction

Additional caution with dopaminergic drugs, clonidine, halogenated anaesthetics , antihypertensive drugs

4.6

Pregnancy and Lactation

Pregnancy:Addition of reports of neonatal cardioresipiratory toxicity, specifically foetal tachycardia and respiratory distress

Lactation: methylphenidate has been found in breast milk, one case report of  weight decrease

4.7

Effects of ability to drive and use machines

Visual disturbances including blurred vision may affect ability to drive or operate machinery

4.8

Undesirable effects

Table has been re-formatted with new system organ classes.In crease in number and type of psychiatric side effects including suicide. Also reports of cerebrovascular accident , neuroleptics malignant syndrome, choreoatheroid movements, hyperhidrosis, muscle cramps, gynaecomastia

4.9

Overdose

No new information section re-written

 

5.3

Preclinical Safety Data

No new information section re-written

 

10.

DATE OF REVISION OF THE TEXT

 

Changed to Ferbruary 2010

 

Updated on 08 February 2010

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision
  • Change due to user-testing of patient information

Updated on 12 February 2009

Reasons for updating

  • Introduction of new strength
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

New SPC for new product

New Strength of Concerta XL

8.

MARKETING AUTHORISATION NUMBER(S)

PA 748/49/4

 

9.

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

01 August 08

 

10.

DATE OF REVISION OF THE TEXT

August 08

 

Updated on 12 February 2009

Reasons for updating

  • SPC re-instated

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SmPC retired in error, now re-instated
 

Updated on 12 February 2009

Reasons for updating

  • PIL re-instated

Updated on 01 September 2008

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

7.

MARKETING AUTHORISATION HOLDER

Update address to 50-100 Holmers Farm Way

 

10.

DATE OF REVISION OF THE TEXT

 

Changed to August 2008

 

Updated on 28 August 2008

Reasons for updating

  • Addition of marketing authorisation holder

Updated on 17 October 2007

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
  • Change to separate SPCs covering individual presentations

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.4 – Special Warnings and Precautions for Use

Addition of mania/aggression sub-headings & text

Change to section 4.8 – Undesirable effects

Major revision to update to 2005 SPC guidance

Change to section 10 – Date of revision of the text

Changed to September 2007

Change to separate SPCs covering individual presentations                                                                                                                                                                                                     

 

Updated on 17 October 2007

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 03 September 2007

Reasons for updating

  • Change due to harmonisation of patient information leaflet
  • Change due to user-testing of patient information

Updated on 27 July 2007

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 6.1 - List of excipients
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
  • Change to joint SPC covering all presentations

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.2 – Posology and Method of Administration

Change in position of ‘Children (under 6 years of age) section to beginning of section 4.2.

Change to section 4.4 – Special Warnings and Precautions for Use

Change in position of ‘Use in patients with renal hepatic impairment’ from this section into section 4.2

 

Under section heading ‘Galactose intolreance’ additional statement adding ‘This medicinal product contains lactose’

Change to section 4.5 –Interaction with other medicinal products and other forms of interaction

Addition of cross-references to sections 4.3 and 4.4

Change to section 4.6 – Pregnancy and Lactation

Addition of section headings: ‘Women of childbearing potential/Contraception ; Pregnancy ; Lactation

Change to section 6.1 – List of Excipients

Excipients capitalised and listed sequentially

Change to section 6.6 –  Instructions for use, handling and disposal

Section heading updated

Change to section 9 – Date of Renewal of Authorisation

Updated to add ‘6 June 2007’ ; sub-section headings added

Change to section 10 – Date of revision of the text

Updated to add ‘6 June 2007’

Change to joint SPC covering all presentations                                                                                                                                                                                                                 

 

Updated on 08 March 2007

Reasons for updating

  • Correction of spelling/typing errors

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 16 January 2007

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications

Updated on 11 January 2007

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 4.4 – Special Warnings and Precautions for Use

Updated: warning in patients with cardiac structural abnormalities

Change to section 4.5 –Interaction with other medicinal products and other forms of interaction

Updated INN names for Phenobarbital and amfetamine

Updated on 19 May 2005

Reasons for updating

  • Change to storage instructions
  • Change to warnings or special precautions for use

Updated on 17 May 2005

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.5 - Nature and contents of container

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 16 November 2004

Reasons for updating

  • New PIL for medicines.ie

Updated on 18 March 2004

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 05 June 2003

Reasons for updating

  • New SPC for medicines.ie

Legal category:Product subject to medical prescription which may not be renewed (A)